Drug Profile
Carbamazepine - GT Biopharma
Alternative Names: PainBrakeLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Accu-Break Pharmaceuticals
- Developer GT Biopharma
- Class Analgesics; Antidepressants; Antiepileptic drugs; Antimanics; Dibenzazepines; Neuroprotectants; Small molecules
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO, Tablet)
- 11 Sep 2017 Georgetown Translational Pharmaceuticals has been acquired and merged into GT Biopharma
- 11 Sep 2017 GT Biopharma signs a manufacturing agreement with a New Jersey manufacturing facility for production of PainBrake tablets for Neuropathic pain